Pfizer completes acquisition of two GSK meningitis vaccines

In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis ($NVS), GlaxoSmithKline ($GSK) announced in June that it would sell two of its mature meningitis jabs to Pfizer ($PFE). The $130 million acquisition of Mencevax and Nimenrix has now closed. Both are marketed outside the U.S. and target the A, C, Y and W strains, but not the B strain. More

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.